Literature DB >> 8601631

Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.

B Rehermann1, D Lau, J H Hoofnagle, F V Chisari.   

Abstract

Clearance of the hepatitis B virus (HBV) during acute hepatitis is associated with a strong, polyclonal, multispecific cytotoxic T lymphocyte (CTL) response to the viral envelope, nucleocapsid and polymerase proteins that persists for decades after clinical recovery. In contrast, chronically infected patients usually fail to mount a strong CTL response to this virus. In this study we demonstrate that chronically infected patients who experience a spontaneous or interferon-induced remission develop a CTL response to HBV that is similar in strength and specificity to patients who have recovered from acute hepatitis. The results suggest that specific immunotherapeutic enhancement of the CTL response to HBV should be possible in chronically infected patients, and that it could lead to viral clearance in these individuals with resolution of chronic liver disease.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8601631      PMCID： PMC507230          DOI： 10.1172/JCI118592

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  26 in total

1.  Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion.

Authors:  S L Tsai; P J Chen; M Y Lai; P M Yang; J L Sung; J H Huang; L H Hwang; T H Chang; D S Chen
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

2.  HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen.

Authors:  A Bertoletti; C Ferrari; F Fiaccadori; A Penna; R Margolskee; H J Schlicht; P Fowler; S Guilhot; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

3.  Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection.

Authors:  V Barnaba; A Franco; A Alberti; C Balsano; R Benvenuto; F Balsano
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

4.  Long-term remission of chronic hepatitis B after alpha-interferon therapy.

Authors:  J Korenman; B Baker; J Waggoner; J E Everhart; A M Di Bisceglie; J H Hoofnagle
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

5.  HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection.

Authors:  R Nayersina; P Fowler; S Guilhot; G Missale; A Cerny; H J Schlicht; A Vitiello; R Chesnut; J L Person; A G Redeker; F V Chisari
Journal:  J Immunol       Date:  1993-05-15       Impact factor: 5.422

6.  A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B.

Authors:  A M Di Bisceglie; T L Fong; M W Fried; M G Swain; B Baker; J Korenman; N V Bergasa; J G Waggoner; Y Park; J H Hoofnagle
Journal:  Am J Gastroenterol       Date:  1993-11       Impact factor: 10.864

7.  Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines.

Authors:  S Guilhot; P Fowler; G Portillo; R F Margolskee; C Ferrari; A Bertoletti; F V Chisari
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

8.  Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection.

Authors:  M C Jung; H M Diepolder; U Spengler; E A Wierenga; R Zachoval; R M Hoffmann; D Eichenlaub; G Frösner; H Will; G R Pape
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen.

Authors:  A Penna; F V Chisari; A Bertoletti; G Missale; P Fowler; T Giuberti; F Fiaccadori; C Ferrari
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

10.  HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis.

Authors:  G Missale; A Redeker; J Person; P Fowler; S Guilhot; H J Schlicht; C Ferrari; F V Chisari
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307
View more
  76 in total

Review 1.  Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.

Authors:  F V Chisari
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 2.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

3.  Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection.

Authors:  J Ehrmann; D Galuszková; J Ehrmann; I Krc; V Jezdinská; B Vojtések; P G Murray; Z Koláo
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

4.  Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy.

Authors:  Younhee Park; Yongjung Park; Kwang-Hyub Han; Hyon-Suk Kim
Journal:  J Clin Lab Anal       Date:  2011-11       Impact factor: 2.352

5.  Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population.

Authors:  Lu Wang; Yijin Wang; Shuhong Liu; Xiangwei Zhai; Guangde Zhou; Fengmin Lu; Jingmin Zhao
Journal:  J Gastroenterol       Date:  2019-05-27       Impact factor: 7.527

6.  Detailed characterization of the peptide binding specificity of five common Patr class I MHC molecules.

Authors:  John Sidney; Shinichi Asabe; Bjoern Peters; Kelly-Anne Purton; Josan Chung; Timothy J Pencille; Robert Purcell; Christopher M Walker; Francis V Chisari; Alessandro Sette
Journal:  Immunogenetics       Date:  2006-06-22       Impact factor: 2.846

Review 7.  Molecular virology of hepatitis B virus for clinicians.

Authors:  Timothy M Block; Haitao Guo; Ju-Tao Guo
Journal:  Clin Liver Dis       Date:  2007-11       Impact factor: 6.126

8.  Number of mutations within CTL-defined epitopes of the hepatitis B Virus (HBV) core region is associated with HBV disease progression.

Authors:  Daniel Kim; Kwang Soo Lyoo; Davey Smith; Wonhee Hur; Sung Woo Hong; Pil Soo Sung; Seung Kew Yoon; Sanjay Mehta
Journal:  J Med Virol       Date:  2011-12       Impact factor: 2.327

9.  Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.

Authors:  Kazuhiro Kakimi; Masanori Isogawa; JoSan Chung; Alessandro Sette; Francis V Chisari
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence.

Authors:  Chloe L Thio; Jacquie Astemborski; Arman Bashirova; Timothy Mosbruger; Spencer Greer; Mallory D Witt; James J Goedert; Margaret Hilgartner; Audrey Majeske; Stephen J O'Brien; David L Thomas; Mary Carrington
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.